国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (7): 520-522.doi: 10.3760/cma.j.issn.1673422X.2014.07.012

• 综述 • 上一篇    下一篇

胃癌靶向治疗的研究进展

薛克伟, 李贵新, 王共爱, 姜雨   

  1. 261042 潍坊医学院研究生院(薛克伟、王共爱、姜雨)；潍坊医学院附属医院肿瘤科(李贵新)
  • 出版日期:2014-08-04 发布日期:2014-08-04
  • 通讯作者: 李贵新， Email: liguixin@wfmc.edu.cn E-mail:liguixin@wfmc.edu.cn

Advance of targeted therapy for gastric cancer

 XUE  Ke-Wei, LI  Gui-Xin, WANG  Gong-Ai, JIANG  Yu   

  1. *Graduate School， Weifang Medical University, Weifang 261042，China
  • Online:2014-08-04 Published:2014-08-04
  • Contact: Li Guixin E-mail:liguixin@wfmc.edu.cn

PDF

1369

摘要： 近几年许多治疗胃癌的靶向治疗药物陆续应用于临床。原癌基因人类表皮生长因子受体2（HER2）单克隆抗体曲妥珠单抗在HER2阳性胃癌患者中发挥很好的抗肿瘤效应，已成为胃癌患者的第一靶向治疗药物。单克隆抗体和酪氨酸抑制剂表皮生长因子受体抑制剂有助于延长患者的生存期，哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂和cMet抑制剂类药物也正在进行临床前期或临床期研究。

关键词: 胃肿瘤, 受体, 表皮生长因子, 酶抑制剂, 靶向治疗

Abstract: In recent years many targeted agents treating gastric cancer have been evaluated in clinical studies. Trastuzumab, an antiHER2 monoclonal antibody, has shown activity against HER2positive gastric cancer and become the first targeted agent approved in gastric cancer. Drugs targeting epidermal growth factor receptor, including monoclonal antibody and tyrosine kinase inhibitor, bring survival benefit to patients with gastric cancer. Additionally, vascular endothelial growth factor inhibitors are also under investigation. Other targeted agents are in preclinical or early clinical development, such as mTOR inhibitors and cMET inhibitors.

Key words: Stomach neoplasms, Receptor, epidermal growth factor, Enzymeinhibitors, Targeted therapy